| BAY u3405DP2 receptor antagonist |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
BAY u3405 Dilution Calculator
calculate
BAY u3405 Molarity Calculator
calculate
| Cas No. | 116649-85-5 | SDF | Download SDF |
| Synonyms | Ramatroban | ||
| Chemical Name | 3R-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid | ||
| Canonical SMILES | O=S(N[C@H](CC1)CC2=C1N(CCC(O)=O)C3=CC=CC=C23)(C4=CC=C(F)C=C4)=O | ||
| Formula | C21H21FN2O4S | M.Wt | 416.5 |
| Solubility | ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
IC50: 100-170 nM
BAY u3405 is a DP2 receptor antagonist.
The biological effects of prostaglandin D2 (PGD2) are transduced by at least two 7-transmembrane G protein-coupled receptors, designated DP1 and DP2/CRTH2.
In vitro: BAY u3405 showed significant inhibitory effects on the binding of 3H-labeled PGD2 to CRTH2, albeit with much lower potency. BAY u3405 and indomethacin also inhibited PGD2-induced Ca2+ mobilization in CRTH2 transfectants to almost the same extent. However, indomethacin but not BAY u3405 was confirmed as an agonist of Ca2+ mobilization at concentrations greater than 10 nM [1].
In vivo: For rat with splanchnic artery occlusion shock, administration of BAY u3405 at 30 mg/kg i.v. could significantly increase the survival time and survival rate, improve mean arterial blood pressure, reduce the plasma levels of myocardial depressant factor, partially restore macrophage phagocytosis and lower MPO activity in both the ileum and the lung [2].
Clinical trial: Twelve adult asthmatics were studied in a randomized, double-blind, placebo-controlled study. Three subjects were withdrawn from the evaluation. The Dmin value of 0.533 U after the BAY u3405 treatment was significantly greater than that of 0.135 U after the placebo treatment. There were no safety concerns in either treatment group [3].
References:[1] Sugimoto, H.,Shichijo, M.,Iino, T., et al. An orally bioavailable small molecule antagonist of CRTH2, Ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. Journal of Pharmacology and Experimental Therapeutics 305, 347-352 (2003).[2] Canale P, Squadrito F, Altavilla D, Ioculano M, Campo GM, Squadrito G, Urna G, Sardella A, Caputi AP. Beneficial effects of BAY u3405, a novel thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock. Pharmacology. 1994 Dec;49(6):376-85.[3] Aizawa H, Shigyo M, Nogami H, Hirose T, Hara N.BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest. 1996 Feb;109(2):338-42.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
请教各位大神，我最近在做WB，565KD的蛋白，动物组织的样品，听说样品制备需要蔗糖裂解液，请问这个是必须的嘛？用一般蛋白提取方法制备可以吗？还有电泳和转膜条件能否分享一下。不胜感激
脂质的生物学功能有1、脂肪氧化分解释放能量
2、复合脂质和衍生脂质是构成细胞的成分
3、促进脂性维生素的吸收
4、脂肪防震和隔热保温作用
5、脂肪的氧化利用具有降低蛋白质和糖消耗的作用
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.
脂质(Lipids)又称脂类,是脂肪及类脂的总称.这是一类不溶于水而易溶于脂肪溶剂(醇、醚、氯仿、苯)等非极性有机溶剂。并能为机体利用的重要有机化合物。脂质包括的范围广泛，其分类方法亦有多种。通常根据脂质的主要组成成分分为：简单脂质、复合脂质、衍生脂质、不皂化脂类。
基本介绍
不溶于水而能被乙醚、氯仿、苯等非极性有机溶剂抽提出的化合物，统称脂类。
脂类包括油脂（甘油三酯）和类脂（磷脂、蜡、萜类、甾类）。
脂类是机体内的一类有机小分子物质，它包括范围很广，其化学结构有很大差异，生理功能各不相同，其共同物理性质是不溶于水而溶于有机溶剂，在水中可相互聚集形成内部疏水的聚集体（如右图）。
脂类是油、脂肪、类脂的总称。食物中的油脂主要是油和脂肪，一般把常温下是液体的称作油，而把常温下是固体的称作脂肪.
固醇（sterol） 又称甾醇。类固醇的一种。固醇类化合物广泛分布于生物界。用碱性溶液提取动植物组织中的脂类，其中常有多少不等的、不能为碱所皂化的物质，它们均以环戊烷多氢菲为基本结构，并含有醇基，故称为固醇类化合物。胆固醇是高等动物细胞的重要组分。它与长链脂肪酸形成的胆固醇酯是血浆脂蛋白及细胞膜的重要组分。植物细胞膜则含有其它固醇如豆固醇及谷固醇。真菌和酵母则含有菌固醇。胆固醇是动物组织中其它固醇类化合物如胆汁醇、性激素、肾上腺皮质激素、维生素D3等的前体。
westblot蛋白免疫印迹实验跑小分子蛋白（15kd）条带一直是波浪状，有人说是胶的问题，可同时跑了36kd蛋白，条带是直的，有人说是要恒流跑，电压不要太大，我的转膜条件是50v，50min，请教各位大神指点，万分感谢！！！
